Today's Healthcare Pulse
Pharma Shifts Ad Spend to Spot TV Amid Heightened FDA Scrutiny
Pharmaceutical advertisers are redirecting dollars toward spot television placements as the FDA intensifies its oversight of drug marketing. The trend reflects a strategic move to capture audiences with shorter, targeted ads while navigating tighter regulatory expectations.
Also developing:
By the numbers: Apogee Therapeutics secures $1.3B royalty financing
FDA Grants Accelerated Approval to Gilead’s Hepcludex, First U.S. HDV Therapy
The U.S. FDA has granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide‑gmod) 8.5 mg, creating the first FDA‑cleared therapy for chronic hepatitis delta virus (HDV) in the United States. The decision rests on Phase 3 MYR301 data showing virologic and biochemical improvements, and it opens a treatment option for an estimated 40,000‑80,000 U.S. patients who currently have no approved drugs.
Prevent Denials by Catching Credentialing Issues
Billings Clinic–Logan Health avoided costly claim denials by overhauling its provider credentialing checks. Compliance partner Ximena Restrepo says manual verification of physicians against federal and state exclusion lists can prevent $100,000 per claim‑line penalties and $24,947 civil fines. The hospital...
Dual-Center Development and Validation of a LDL-C and TC Based Nomogram for Preoperative Hemorrhagic Risk in Adult Moyamoya Disease
A dual‑center retrospective study of 260 adult moyamoya disease (MMD) patients identified elevated low‑density lipoprotein cholesterol (LDL‑C) as an independent predictor of pre‑operative intracranial hemorrhage. Using LASSO and multivariate logistic regression, the authors built a nomogram incorporating LDL‑C and total...
The Quiet Loss of Dignity in Medicine
Developmental‑behavioral pediatrician Ronald L. Lindsay warns that American medicine is losing its dignity as corporate pressures silence honest discourse. He illustrates the crisis with the case of an 18‑month‑old ICE detainee denied basic COVID‑19 treatments, highlighting how policy overrides patient...
Fragments in the Clinic: VVD-214
Vividion’s covalent WRN inhibitor VVD‑214 evolved from a vinyl‑sulfone fragment hit (compound 1a) to a clinically viable candidate through a series of empirical SAR steps. Introducing a methyl group (2a) boosted stability and sub‑micromolar cellular potency, while a tert‑butyl cyclopentyl...
Emagene.Life Teams with Adam Health to Roll Out AI‑Powered Longevity Sensors in SE Asia
Emagene.Life and Adam Health announced a strategic alliance to bring the Adam Health sensor and AI‑backed longevity platform to Malaysia and Singapore. The deal combines functional‑medicine expertise with real‑time biodata, aiming to give men measurable insights into energy, hormones, and...
Clinical Operations Burnout Is Undermining Patient Enrollment
Clinical operations burnout is eroding patient enrollment and retention in trials, with nearly half of healthcare workers reporting burnout symptoms in 2022. Around 80% of studies miss their recruitment timelines, a problem tied to overburdened site teams handling growing protocol...
Blockbuster Sales, Lawsuits, and Approvals: Is There a Recovery in Sight for Bayer in 2026?
Bayer’s 2026 outlook mixes strong Crop Science sales with a mixed pharma portfolio. Crop Science generated $15.6 billion in Q1, while blockbuster drugs Nubeqa and Kerendia posted double‑digit growth, but Xarelto and Eylea revenues fell sharply after patent expirations. The company...
UAMS Posts $16.7 Million Profit, Reverses $15.9 Million Loss in FY24
The University of Arkansas for Medical Sciences (UAMS) posted a $16.7 million profit through April, flipping a $15.9 million loss from the same period last year. CFO Amanda George credited rising clinic visits, surgical cases and transfer rates, while Chancellor C. Lowry...
Uganda Reports Five Ebola Cases as Outbreak Spreads From Congo
Uganda's health ministry confirmed five Ebola cases, up from earlier reports, after the virus crossed from the Democratic Republic of Congo. The rise has triggered intensified screening at borders and renewed calls for regional coordination to contain the Bundibugyo strain.
REGENXBIO's RGX-202 Gene Therapy Hits Pivotal Efficacy Endpoint in Duchenne Trial
REGENXBIO announced that its one‑time AAV microdystrophin therapy RGX-202 met the primary endpoint in the pivotal phase III AFFINITY DUCHENNE trial, with 93% of evaluable patients showing at least 10% protein expression at week 12. The result positions the company...
:max_bytes(150000):strip_icc():format(jpeg)/outofpocket.asp-final-8fdb440da19e4e2b939a9f85d370afb9.png)
Understanding Out-of-Pocket Expenses: Definition, Types, and Examples
Out-of-pocket expenses are the cash amounts individuals pay before insurance or employer reimbursement, covering both everyday business costs and health‑care charges such as deductibles, copays and coinsurance. The Affordable Care Act caps annual out-of-pocket limits—$9,200 for individuals in 2025, rising...
Army Ranger’s Psilocybin Journey Shows New Standard Care
The Army Ranger Who Found Magic Mushrooms Save Lives. My conversation with Neil Markey — 75th Ranger Regiment, Harvard Chan, Beckley Retreats — was the cleanest case this year for why psilocybin is moving from fringe to standard-of-care. Neuroplasticity. "Betterment of the...
Dr. Oz Fires Back After Joy Behar's TrumpRx Meltdown
President Trump announced that the TrumpRx website will now list more than 600 generic medications, thanks to new deals with Amazon Pharmacy, GoodRx and Mark Cuban’s Cost Plus Drugs. The expansion is framed as a response to rising out‑of‑pocket costs after...
Agios Reports the EC Approval of Pyrukynd for Anemia in Alpha or Beta Thalassemia
The European Commission has granted approval for Agios' oral pyruvate kinase activator Pyrukynd (mitapivat) to treat anemia in adults with both non‑transfusion‑dependent and transfusion‑dependent alpha‑ or beta‑thalassemia. The decision follows positive results from the global Phase III ENERGIZE and ENERGIZE‑T trials,...
Vertical Integration Hijacks Search Rankings, Controls Patient Flow
A practicing psychiatrist Googled her own name and was the 452nd result. The first seven clinics that came up were not hers. The clinic ranked first had no clinical staff she had ever met. This is vertical integration in U.S....
Doctors Warn GLP‑1 Weight‑Loss Drugs Fuel Rise in Eating‑Disorder Cases
U.S. doctors are sounding the alarm as misuse of GLP‑1 weight‑loss medications like Wegovy and Ozempic spikes among people with eating disorders. A recent report estimates more than 420,000 patients could develop an eating disorder from long‑term use, prompting calls...
Maternal Mental Health Tops Death Causes as Flora’s Walk Highlights Crisis
CDC analysis reveals mental‑health conditions accounted for 27.7% of U.S. maternal deaths in 2022, making them the leading cause. At the same time, Thunder Bay’s Flora’s Walk gathered thousands to spotlight perinatal mental‑health struggles, underscoring a growing public‑health emergency.
Eli Lilly’s Retatrutide Delivers up to 30% Weight Loss in Phase 3 Trial
Eli Lilly announced that its experimental triple‑agonist retatrutide produced an average 28.3% weight loss (about 70 lb) in the highest dose group of its Phase 3 TRIUMPH‑1 trial, with nearly half of those participants shedding at least 30% of body weight. The result...
Do Wall Street Analysts Like ResMed Stock?
ResMed Inc., a $30.3 billion market‑cap leader in sleep‑apnea and respiratory devices, has seen its stock tumble 15.3% over the past year, underperforming the S&P 500’s 27.9% gain. Year‑to‑date, the shares are down 13.6% while the broader market rose 9.2%. The company...
Eisai Sets FY2028 Revenue Goal of ¥1 Trillion ($6.7B) on Oncology, Dementia Growth
Japanese drugmaker Eisai announced a FY2028 revenue target of ¥1 trillion (about $6.7 bn), underpinned by projected sales of its Alzheimer’s antibody Leqembi, insomnia drug Dayvigo and cancer therapy Lenvima. The guidance marks a steep climb from FY2025 and signals confidence in...
Pharming Reports the EC Approval of Joenja (Leniolisib) for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
The European Commission has granted marketing authorization for Pharming’s oral PI3Kδ inhibitor Joenja (leniolisib) to treat patients aged 12 and older with activated phosphoinositide 3‑kinase delta syndrome (APDS) across all 30 EEA states. Approval is based on a Phase II/III...
Study Finds Medicare Advantage Plans Leave Mental‑Health Coverage Gap for Seniors
A recent study and government reports reveal that Medicare Advantage plans provide access to roughly half the mental‑health providers available under traditional Medicare, creating a coverage gap that could force retirees to switch plans or pay out‑of‑pocket for needed care.
Arson Attacks on Ebola Treatment Centers Push Suspected Cases in Eastern Congo Past 900
Arson attacks on two Ebola treatment centers in Ituri Province have ignited community anger and forced health workers to scramble as suspected cases climb to 904, with 119 suspected deaths. The violence underscores deep mistrust, rebel activity and dwindling international...
Alcidian Secures $23 Million Deal with University Hospitals Sussex for Miya Precision EPR Platform
Alcidian Group announced a 7‑year contract worth about A$35 million ($23 million) with University Hospitals Sussex to implement its Miya Precision electronic patient record (EPR) platform. The agreement will generate roughly A$8.5 million ($5.6 million) in revenue for Alcidian in fiscal 2026, expanding the...
Jardine Matheson to Acquire I-MED for $2.4 B, Expanding B2B Healthcare Tech Portfolio
Hong Kong‑listed Jardine Matheson Holdings agreed to buy I‑MED Radiology Network for an enterprise value of A$3.4 billion (≈US$2.4 billion). The deal gives Jardine full control of 215 diagnostic imaging clinics across Australia and New Zealand and a minority stake in AI firm...
The Intersection of Medicine and Surgery in Obesity
New data reveal a 34% drop in bariatric surgery volumes between 2022 and 2024, while GLP‑1 drug prescriptions surged 140%, highlighting a shifting treatment landscape. A Nature Medicine trial showed that adding semaglutide 2.4 mg weekly to patients who had insufficient...
Clinical Trial Endpoint by Counting Hairs - Story of Clinical Trials in Androgenetic Alopecia (Hair Loss)
Veradermics announced that its extended‑release oral minoxidil (VDPHL01) met primary endpoints in a pivotal Phase 2/3 trial of 519 men with androgenetic alopecia. The study showed a mean increase of 30.3 hairs/cm² (once‑daily) and 33.0 hairs/cm² (twice‑daily) in non‑vellus target‑area hair...
We Are the Largest Oncology Player in India, Says Zydus MD; Eyes US Speciality Push
Zydus Lifesciences says it has become India’s largest oncology player, leveraging early entry into biologics like Pertuzumab and Nivolumab and a broad oral cancer portfolio. The company attributes rapid growth to government cancer schemes and robust patient‑support programs that have...
Caliway Secures FDA Clearance for CBL-514 Clinical Trial
Caliway Biopharmaceuticals received FDA clearance for its CBL‑0302 IND application, clearing the path for a pivotal global Phase III trial of CBL‑514 aimed at reducing abdominal subcutaneous fat. The double‑blind, placebo‑controlled study will enroll roughly 320 participants in the United States, Canada...
The Bedrock of Containment: Why Sanitation Is the Key to Controlling Ebola
The blog post by Dr. Peter A. McCullough argues that effective sanitation and strict barrier control are the cornerstone of Ebola containment, citing the Czerniewska and White (2020) case study of Liberia’s 2014‑2016 outbreak. It stresses that Ebola spreads through...
Late-Breakers to Look Out for at ASCO 2026
ASCO 2026’s late‑breaker session will unveil a slate of pivotal trials that could reshape treatment algorithms across liver, bladder, pancreatic, prostate, multiple myeloma and several rare cancers. AstraZeneca will present EMERALD‑3 and POTOMAC data, pushing its Imfinzi‑based combos into first‑line...
Newel Health and Gerresheimer Launch Strategic Collaboration
Newel Health, a developer of regulated digital medical devices, and Gerresheimer, a global drug‑delivery and packaging specialist, announced a strategic collaboration to help pharmaceutical and biotech firms embed digital endpoints, real‑world data and AI into therapies. The partnership pairs Newel’s...
Gilead Reports the US FDA Accelerated Approval of Hepcludex to Treat Chronic Hepatitis Delta Virus (HDV) Infection
Gilead Sciences received accelerated approval from the U.S. Food and Drug Administration for Hepcludex (bulevirtide‑gmod), an 8.5 mg subcutaneous injection for adults with chronic hepatitis delta virus (HDV) infection. The decision is based on data from the Phase III MYR301 trial, which...
Jardines Signals Pivot with $2.4bn Australian Radiology Deal
Jardine Matheson announced a $2.4 billion acquisition of an Australian radiology network, adding roughly 100 imaging centres to its portfolio. The deal is financed with $1 billion of cash and $1.4 billion of debt, reflecting the conglomerate’s push into health services. The move...
Healthcare Outsourcing Philippines: How AI Is Redefining Patient Care Delivery
In 2026 the Philippines has evolved from a low‑cost health‑BPO destination to a hub for AI‑augmented clinical operations, a shift dubbed “Intelligence‑Augmented Care.” Vendors are moving from headcount‑based pricing to outcome‑aligned models, delivering up to 45 % lower claim denial rates...
Permira Sells I‑MED to Jardine Matheson for $3.4 Billion
London‑based buyout firm Permira has agreed to sell its European medical‑device platform I‑MED to Hong Kong‑listed conglomerate Jardine Matheson for an enterprise value of $3.4 billion. The transaction gives Jardine Matheson full ownership of the Asia‑Pacific’s largest radiology business and signals...
Regeneron’s Melanoma Immunotherapy Misses Primary Endpoint, Shares Plunge
Regeneron Pharmaceuticals announced that its late‑stage melanoma trial combining the antibody fianlimab with PD‑1 inhibitor cemiplimab failed to meet its primary endpoint, prompting a double‑digit intraday share decline and prompting law‑firm investigations into prior disclosures. The setback raises questions about...
Qualtrics Completes $6.75 Bn Acquisition of Press Ganey Forsta, Expanding Healthcare Data Reach
Qualtrics has closed a $6.75 billion purchase of Press Ganey Forsta, instantly giving its Experience Management platform access to more than 41,000 U.S. healthcare facilities. The deal is aimed at turning patient and staff feedback into predictive insights that can improve...
Three Hospital Systems Sue CVS Over Alleged $250 Million 340B Savings Misuse
Mount Sinai, University of Michigan Health and the University of Kansas Hospital Authority have filed lawsuits accusing CVS Health of diverting roughly $250 million in 340B drug‑pricing savings. The complaints claim CVS kept the spread as profit, prompting demands for damages...
New Advances Improve Prevention and Treatment of HPV-Related Cancers
Human papillomavirus remains a leading cause of cervical, anal, oropharyngeal and other cancers. New prophylactic vaccines now protect against a broader set of high‑risk strains, while next‑generation candidates aim for even wider coverage. Therapeutic vaccines that target the viral E6...
Hong Kong Hospital Authority Introduces Standardised Caller ID Prefixes to Help Public Identify Official Calls
Hong Kong's Hospital Authority will roll out standardized caller ID prefixes for its facilities starting 26 May 2026, using numbers 1828 500–1828 699. The initiative aims to help residents quickly recognize legitimate hospital calls and reduce missed urgent communications amid rising spam and scam...
Medicare Launches $50‑a‑Month GLP‑1 Bridge, Slashing Wegovy and Zepbound Costs
Medicare will begin a $50 monthly copay pilot for the GLP‑1 drugs Wegovy and Zepbound on July 1, cutting seniors’ out‑of‑pocket costs from roughly $1,300 to $50. The demonstration runs through Dec. 31, 2027 and targets beneficiaries with cardiovascular disease or obstructive...
Junshi Biosciences Wins China NMPA Approval for Loqtorzi HER2‑Urothelial Cancer Combo
Junshi Biosciences announced that China’s National Medical Products Administration has approved Loqtorzi, a toripalimab‑disitamab vedotin combo, for first‑line treatment of HER2‑expressing advanced urothelial carcinoma. The Phase III trial showed median progression‑free survival of 13.1 months and overall survival of 31.5 months, far outpacing...
Building a Precision Therapy Corridor
Brussels Airport is launching the Precision Therapies Logistics Gateway (PTLG) to build an international corridor for transporting cell, gene and radioligand therapies with near‑clinical precision. Backed by Air Cargo Belgium, at.las, Pharma.aero and regional governments, the project has already run...
Stem‑Cell Transplants Restore Insulin Production in Type 1 Diabetes, Early Trial Shows
Researchers reported that stem‑cell‑derived beta cell transplants restored measurable insulin production in a small cohort of Type 1 diabetes patients. The early results demonstrate that lab‑grown cells can survive, mature and function after implantation, offering a potential regenerative route for a...
Declining Physical Activity May Signal Cognitive Changes in Older Adults
A 17‑year UK cohort study of 2,529 adults aged 50 and older found that greater memory decline is linked to less light physical activity and more sedentary time. Participants with slower memory loss logged roughly 14 extra minutes of light...
Abridge Names Former Notion and Slack Exec San Oo as CTO
Healthcare AI startup Abridge announced the appointment of San Oo, former senior vice president of engineering at Notion and former senior engineering leader at Slack, as its new chief technology officer. Oo replaces Zachary Lipton, who moves to a science...
Asundexian Cuts Recurrent Stroke Risk 26% Without Raising Bleeding in Global Phase 3 Trial
In the OCEANIC-STROKE Phase 3 trial, asundexian lowered recurrent stroke risk by 26% without elevating major bleeding rates, a result that could reshape secondary stroke prevention. The study enrolled 12,327 patients across 37 countries, comparing daily 50 mg asundexian to placebo...
Screening Indigenous People for This Heart Condition at 55 Can Prevent Strokes and Save Lives
New research published in the Medical Journal of Australia shows that Aboriginal and Torres Strait Islander Australians develop atrial fibrillation about 16 years earlier than non‑Indigenous peers, making strokes up to twice as likely. Screening the Indigenous population from age...